Claims for Patent: 9,546,369

Summary for Patent: 9,546,369

Title:	Multicistronic expression constructs
Abstract:	Some aspects of this invention provide nucleic acid constructs for transgene expression. Some aspects of this invention provide multicistronic nucleic acid constructs, for example, comprising an expression cassette encoding a hairpin RNA and a reporter expression cassette. Some aspects of this invention provide nucleic acid constructs comprising two or more self-complementary nucleic acid sequences, for example, hairpin RNA encoding nucleic acid sequences and AAV inverse terminal repeats. Methods for the use of the constructs in therapy and research are also provided.
Inventor(s):	Gao; Guangping (Westborough, MA), Xie; Jun (Shrewsbury, MA)
Assignee:	University of Massachusetts (Boston, MA)
Application Number:	13/642,747
Patent Claims:	1. A recombinant nucleic acid construct, comprising a recombinant AAV (rAAV) vector comprising inverted terminal repeats (ITRs); a first expression cassette, comprising a nucleic acid encoding a gene product heterologous to the vector under the control of a first promoter positioned between the ITRs of the vector, and an intron, wherein the intron is positioned between the transcriptional start site of the first expression cassette and the nucleic acid encoding the gene product, and a second expression cassette, comprising a self-complementary nucleic acid sequence under the control of a second promoter, wherein the second expression cassette is positioned within the intron of the first expression cassette in proximity with the first promoter. 2. The nucleic acid construct of claim 1, wherein the first promoter is an RNA polymerase II promoter. 3. The nucleic acid construct of claim 1, wherein the second promoter is an RNA polymerase III promoter or a U6 or an H1 promoter. 4. A plasmid comprising the nucleic acid construct of claim 1. 5. A composition comprising the nucleic acid construct of claim 1. 6. The composition of claim 5, further comprising a pharmaceutically acceptable salt. 7. A kit, comprising a container housing the nucleic acid construct of claim 1. 8. A non-human cell, comprising a nucleic acid construct of claim 1. 9. The cell of claim 8, wherein the cell is comprised in a non-human subject. 10. The recombinant nucleic acid construct of claim 1, wherein the rAAV vector is configured such that the direction of transcription of the first expression cassette and the direction of transcription of the second expression cassette are opposed. 11. The recombinant nucleic acid construct of claim 1, wherein the rAAV vector is configured such that the direction of transcription of the first expression cassette and the direction of transcription of the second expression cassette are the same. 12. The recombinant nucleic acid construct of claim 1, wherein the gene product is a reporter protein. 13. The recombinant nucleic acid construct of claim 12, wherein the reporter protein is a fluorescent protein, enzyme or surface antigen. 14. The recombinant nucleic acid construct of claim 1, wherein the self-complementary nucleic acid encodes self-complementary RNA. 15. The recombinant nucleic acid construct of claim 14, wherein the self-complementary RNA is shRNA or miRNA. 16. The recombinant nucleic acid construct of claim 15, wherein the shRNA or miRNA is complementary to a messenger RNA (mRNA). 17. The recombinant nucleic acid construct of claim 16, wherein the mRNA is human mRNA. 18. The recombinant nucleic acid construct of claim 1, wherein at least one of the ITRs is an AAV1 ITR, AAV2 ITR, AAV3 ITR, AAV4 ITR, AAV5 ITR, or AAV6 ITR. 19. The recombinant nucleic acid construct of claim 1, wherein one of the ITRs lacks a functional terminal resolution site. 20. The recombinant nucleic acid construct of claim 19, wherein the ITR lacking a functional terminal resolution site is a .DELTA.TRS ITR. 21. A method, comprising contacting a cell expressing a target gene with the nucleic acid construct of claim 1. 22. The method of claim 21, wherein the gene product is a reporter, and wherein the method further comprises detecting expression of the reporter in the cell. 23. The method of claim 21, further comprising determining a change in the phenotype of the cell after the contacting.

Details for Patent 9,546,369

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2030-04-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2030-04-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2030-04-23